Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study

BACKGROUND: Regorafenib is a multi-kinase inhibitor, which was shown to be effective for patients with metastatic colorectal cancer refractory to standard therapies. However, its patterns of response has not yet been fully understood. METHODS: Clinical records of 10 patients who received regorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaki, Yukinori, Shindoh, Junichi, Gonoi, Wataru, Nishioka, Yujiro, Kondoh, Chihiro, Tanabe, Yuko, Matoba, Shuichiro, Kuroyanagi, Hiroya, Hashimoto, Masaji, Takano, Toshimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800281/
https://www.ncbi.nlm.nih.gov/pubmed/29402244
http://dx.doi.org/10.1186/s12885-018-4067-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800281/
https://www.ncbi.nlm.nih.gov/pubmed/29402244
http://dx.doi.org/10.1186/s12885-018-4067-5

Ejemplares similares